Drug Shortage Report for APRESOLINE
Report ID | 58938 |
Drug Identification Number | 00723754 |
Brand name | APRESOLINE |
Common or Proper name | Hydralazine Hydrochloride for injection |
Company Name | STERIMAX INC |
Market Status | DORMANT |
Active Ingredient(s) | HYDRALAZINE HYDROCHLORIDE |
Strength(s) | 20MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS |
Packaging size | 10 vials |
ATC code | C02DB |
ATC description | ARTERIOLARSMOOTH MUSCLE, AGENTS ACTING ON |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2018-09-28 |
Actual start date | |
Estimated end date | |
Actual end date | 2019-02-27 |
Shortage status | Resolved |
Updated date | 2019-02-28 |
Company comments | Product is on 125% allocation at McKesson. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 2770 PORTLAND DRIVE OAKVILLE, ONTARIO CANADA L6H 6R4 |
Company contact information | 1-800-881-3550 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2018-08-24 | English | Compare |